8-K: INVO Bioscience and NAYA Biosciences Amend Merger Agreement, Extend Deadline to October 14

INVO Bioscience and NAYA Biosciences have agreed to a fourth amendment of their merger agreement, extending the deadline to October 14, 2024, and modifying the terms of the deal.

Summary

• INVO Bioscience and NAYA Biosciences have amended their merger agreement for the fourth time, extending the deadline for the merger to October 14, 2024.
• NAYA will purchase 27,500 shares of INVO's Series A Preferred Stock for $137,500 and may purchase up to an additional 72,500 shares for $362,500 before or during the merger closing.
• Both parties have waived prior breaches of the merger agreement and will work towards finalizing the merger by October 1, 2024, but no later than October 14, 2024.
• The merger consideration will include INVO common stock representing no more than 19.9% of outstanding shares and newly designated Series C Convertible Preferred Stock.
• 85% of the common stock payment will be transferred to Five Narrow Lane LP, a secured lender of NAYA.
• INVO will hold a stockholder meeting within 120 days of the merger closing to approve the conversion of the preferred stock, with a proxy statement to be filed within 35 days of closing.
• Upon stockholder approval, the preferred stock will convert to common stock, representing approximately 60.1% of INVO's outstanding shares.
• INVO will file a resale registration statement for the common stock and the converted shares after the merger.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the merger is progressing, the repeated delays and significant dilution of common stock are concerning. The involvement of a secured lender also adds a layer of complexity.

Positives

• The merger agreement is progressing with a clear timeline for closing.
• The purchase of preferred stock by NAYA provides immediate capital to INVO.
• The parties have waived prior breaches, indicating a commitment to the merger.
• The revised structure aims to comply with Nasdaq listing and governance rules.
• The agreement includes a plan for a stockholder meeting to approve the conversion of preferred stock.

Negatives

• The merger has been delayed multiple times, requiring four amendments to the original agreement.
• The significant portion of common stock going to a lender (85% to Five Narrow Lane LP) may dilute existing shareholders.
• The potential for a stockholder meeting to be delayed due to SEC comments introduces uncertainty.
• The conversion of preferred stock could result in a significant dilution of existing common stock, with the converted shares representing approximately 60.1% of the outstanding shares.

Risks

• The merger could be further delayed or terminated if the parties fail to agree on the amended and restated merger agreement.
• The merger is subject to stockholder approval, which may not be obtained.
• The significant dilution of existing common stock could negatively impact the share price.
• The transfer of a large portion of the common stock to a lender could create instability in the shareholding structure.

Future Outlook

The parties are committed to closing the merger by October 14, 2024, and will work towards finalizing the amended agreement and obtaining stockholder approval for the conversion of preferred stock.

Management Comments

• The parties agreed to use their best efforts to consummate the transactions contemplated by the Fourth Amendment.
• The parties will negotiate in good faith to amend and restate the Merger Agreement.

Industry Context

The merger is occurring in the biotechnology sector, where mergers and acquisitions are common as companies seek to expand their portfolios and market reach. The specific focus on reproductive health by INVO and NAYA suggests a strategic alignment within this niche market.

Comparison to Industry Standards

• The use of preferred stock and common stock in merger consideration is a common practice in the biotech industry, often used to balance immediate cash needs with long-term equity incentives.
• The 19.9% cap on common stock issuance is likely to avoid triggering certain shareholder approval requirements, a common tactic in mergers.
• The 60.1% ownership stake for the converted preferred stock is a significant dilution, which is not uncommon in mergers involving companies with different valuations and capital structures.
• The involvement of a secured lender (Five Narrow Lane LP) receiving a large portion of the common stock is a unique aspect of this deal, potentially indicating financial constraints or strategic debt management.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new common stock and the conversion of preferred stock.
• Employees of both companies may experience uncertainty during the merger process.
• Creditors of NAYA may be impacted by the transfer of common stock to Five Narrow Lane LP.
• Customers and suppliers may experience changes as the two companies integrate.

Next Steps

• The parties will negotiate in good faith to finalize the amended and restated merger agreement.
• INVO will hold a stockholder meeting to approve the conversion of the preferred stock.
• INVO will file a resale registration statement for the common stock and the converted shares.

Key Dates

Keywords

merger, acquisition, INVO Bioscience, NAYA Biosciences, preferred stock, common stock, stockholder approval, Nasdaq, dilution, Five Narrow Lane LP